JP2015511958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511958A5
JP2015511958A5 JP2014560985A JP2014560985A JP2015511958A5 JP 2015511958 A5 JP2015511958 A5 JP 2015511958A5 JP 2014560985 A JP2014560985 A JP 2014560985A JP 2014560985 A JP2014560985 A JP 2014560985A JP 2015511958 A5 JP2015511958 A5 JP 2015511958A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
compound
acceptable salt
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560985A
Other languages
English (en)
Other versions
JP2015511958A (ja
JP6161643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028796 external-priority patent/WO2013134085A1/en
Publication of JP2015511958A publication Critical patent/JP2015511958A/ja
Publication of JP2015511958A5 publication Critical patent/JP2015511958A5/ja
Application granted granted Critical
Publication of JP6161643B2 publication Critical patent/JP6161643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. 下記:
    Figure 2015511958

    Figure 2015511958

    Figure 2015511958

    より選択される構造式によって表される化合物、又はその薬学的に許容し得る塩。
  2. 医薬としての使用のための、請求項1記載の化合物又はその薬学的に許容し得る塩。
  3. 薬学的に許容し得る佐剤、希釈剤及び/もしくは担体と混合した請求項1記載の少なくとも1つの化合物又はその薬学的に許容し得る塩を含む、医薬組成物。
  4. BACE1介在の障害又は疾患の処置における使用のための、請求項1記載の化合物又はその薬学的に許容し得る塩。
  5. BACE1介在の障害又は疾患が、神経変性障害、認知機能低下、認知機能障害、認知症、及びβ−アミロイド沈着又は神経原線維変化の産生により特徴付けられる疾患からなる群より選択される、請求項4記載の使用のための化合物又はその薬学的に許容し得る塩。
  6. 障害又は疾患が、アルツハイマー病、トリソミー21(ダウン症)、オランダ型遺伝性アミロイドーシス脳出血(HCHWA−D)、老年認知症、脳アミロイド血管症、変性認知症、血管及び変性由来の混合型認知症、パーキンソン病に関連する認知症、進行性核上性麻痺に関連する認知症、皮質基底変性に関連する認知症、アルツハイマー病のびまん性レビー小体型、萎縮型加齢黄斑変性症(AMD)及び緑内障からなる群より選択される、請求項5記載の使用のための化合物又はその薬学的に許容し得る塩。
  7. 障害又は疾患が、アルツハイマー病である、請求項6記載の使用のための化合物又はその薬学的に許容し得る塩。
  8. 障害又は疾患が、緑内障である、請求項6記載の使用のための化合物又はその薬学的に許容し得る塩
  9. 記:
    Figure 2015511958

    からなる群より選択される化合物;又はその塩。
  10. Figure 2015511958

    の構造を有する化合物、又はその塩。
  11. Figure 2015511958

    の構造を有する化合物、又はその塩。
  12. Figure 2015511958

    の構造を有する化合物、又はその塩。
  13. Figure 2015511958

    の構造を有する化合物、又はその塩。
JP2014560985A 2012-03-05 2013-03-04 β−セクレターゼ阻害剤 Expired - Fee Related JP6161643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606786P 2012-03-05 2012-03-05
US61/606,786 2012-03-05
PCT/US2013/028796 WO2013134085A1 (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase

Publications (3)

Publication Number Publication Date
JP2015511958A JP2015511958A (ja) 2015-04-23
JP2015511958A5 true JP2015511958A5 (ja) 2016-04-21
JP6161643B2 JP6161643B2 (ja) 2017-07-12

Family

ID=47902355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560985A Expired - Fee Related JP6161643B2 (ja) 2012-03-05 2013-03-04 β−セクレターゼ阻害剤

Country Status (40)

Country Link
US (4) US8981112B2 (ja)
EP (1) EP2822930B1 (ja)
JP (1) JP6161643B2 (ja)
KR (1) KR20140138774A (ja)
CN (1) CN104271558B (ja)
AP (1) AP4029A (ja)
AR (1) AR090241A1 (ja)
AU (2) AU2013230523B2 (ja)
BR (1) BR112014021269A2 (ja)
CA (1) CA2864143C (ja)
CL (1) CL2014002334A1 (ja)
CO (1) CO7091177A2 (ja)
CY (1) CY1117543T1 (ja)
DK (1) DK2822930T3 (ja)
EA (1) EA024995B1 (ja)
EC (1) ECSP14020640A (ja)
ES (1) ES2568928T3 (ja)
HK (1) HK1205739A1 (ja)
HR (1) HRP20160415T1 (ja)
HU (1) HUE027289T2 (ja)
IL (1) IL233887A (ja)
IN (1) IN2014DN06710A (ja)
MA (1) MA35945B1 (ja)
ME (1) ME02390B (ja)
MX (1) MX353432B (ja)
MY (1) MY171091A (ja)
NZ (1) NZ629239A (ja)
PE (1) PE20141972A1 (ja)
PH (1) PH12014501963A1 (ja)
PL (1) PL2822930T3 (ja)
RS (1) RS54730B1 (ja)
SG (1) SG11201404600VA (ja)
SI (1) SI2822930T1 (ja)
SM (1) SMT201600114B (ja)
TN (1) TN2014000326A1 (ja)
TW (1) TWI557112B (ja)
UA (1) UA113641C2 (ja)
UY (1) UY34654A (ja)
WO (1) WO2013134085A1 (ja)
ZA (1) ZA201405846B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
KR20120001756A (ko) 2009-03-13 2012-01-04 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑
WO2013169531A1 (en) 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Methods for making oxetan-3-ylmethanamines
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β-分泌酶抑制劑
WO2014052398A1 (en) 2012-09-28 2014-04-03 Vitae Pharmaceuticals, Inc. Inhibitor of beta-secretase
EP2922835B1 (en) 2012-11-21 2017-08-09 Boehringer Ingelheim International GmbH Process for making n-sulfinyl alpha-amino amides
AR102202A1 (es) 2014-10-07 2017-02-08 Astrazeneca Ab Compuestos de oxazol y su uso como inhibidores de bace de oxazol
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
CN109906222B (zh) * 2016-09-07 2023-08-01 加利福尼亚大学董事会 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
JP2020516648A (ja) 2017-04-13 2020-06-11 シワ コーポレーション ヒト化モノクローナル終末糖化産物抗体
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN113082209A (zh) * 2021-03-31 2021-07-09 中国科学技术大学 Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
EP0602060A1 (en) 1991-08-28 1994-06-22 PHARMACIA & UPJOHN COMPANY Spirocyclic benzopyran imidazolines, their preparation and their use as potassium channel activators
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
EP2153832B1 (en) 2003-12-15 2016-03-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2578600A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
WO2006009653A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
WO2006044497A2 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2006138217A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
CA2610812A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2007005404A1 (en) 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
CN101233274B (zh) 2005-07-29 2011-03-16 皇家飞利浦电子股份有限公司 从蒸汽熨斗产生蒸汽喷发的方法
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
KR20080050430A (ko) 2005-09-26 2008-06-05 와이어쓰 베타-세크레타제 (bace) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
DE102005057688A1 (de) 2005-12-01 2007-06-14 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums
CN101360737A (zh) 2005-12-19 2009-02-04 惠氏公司 2-氨基-5-哌啶咪唑酮化合物和其用于β分泌酶调节的用途
EP1974278A4 (en) 2005-12-20 2012-01-04 Fieldbus Foundation SYSTEM AND METHOD FOR IMPLEMENTING INSTRUMENTED SAFETY SYSTEMS
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009539983A (ja) 2006-06-12 2009-11-19 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼ阻害薬
JP5109974B2 (ja) 2006-07-18 2012-12-26 アステラス製薬株式会社 アミノインダン誘導体又はその塩
WO2008030412A2 (en) 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
CL2008000784A1 (es) 2007-03-20 2008-05-30 Wyeth Corp Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
PE20090617A1 (es) 2007-03-23 2009-05-08 Wyeth Corp Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2077637B1 (en) 2007-12-12 2020-03-11 Alcatel Lucent System and method for protecting payload information in radio transmission
ES2398017T3 (es) 2008-02-18 2013-03-13 F. Hoffmann-La Roche Ag Derivados de 4,5-dihidro-oxazol-2-il-amina
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AU2009291602B2 (en) 2008-09-11 2013-02-14 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
PE20110777A1 (es) * 2008-11-23 2011-10-29 Pfizer Nuevas lactamas como inhibidores de beta secretasa
KR20120001756A (ko) * 2009-03-13 2012-01-04 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β-分泌酶抑制劑

Similar Documents

Publication Publication Date Title
JP2015511958A5 (ja)
HRP20160415T1 (hr) Inhibitori beta-sekretaze
JP2015512951A5 (ja)
MX2017013483A (es) Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1).
JP2013525444A5 (ja)
RU2014145682A (ru) Органические соединения
EP4275748A3 (en) Compositions and methods for treating cns disorders
JP2016513130A5 (ja)
HRP20160185T1 (hr) Spojevi iminotiadiazin dioksida kao inhibitori bace, smjese i njihova uporaba
JP2015501783A5 (ja)
EP4252848A3 (en) Oxysterols and methods of use thereof
CL2018000036A1 (es) Derivados etinilo
JP2014507455A5 (ja)
JP2016535786A5 (ja)
JP2015537020A5 (ja)
JP2014506907A5 (ja)
JP2015500223A5 (ja)
JP2012521994A5 (ja)
JP2020502092A5 (ja)
JP2013032389A5 (ja)
JP2016503010A5 (ja)
JP2014500861A5 (ja)
JP2015500257A5 (ja)
JP2016510326A5 (ja)
JP2008535860A5 (ja)